Amado J. Zurita-Saavedra

Oncology

1515 Holcombe Blvd Unit 1374
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo).

A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 05, 2025

Polyploid cancer cells reveal signatures of chemotherapy resistance.

Polyploid cancer cells reveal signatures of chemotherapy resistance.

Journal: bioRxiv : the preprint server for biology

Published: September 04, 2024

Polyploid cancer cells reveal signatures of chemotherapy resistance.

Polyploid cancer cells reveal signatures of chemotherapy resistance.

Journal: Oncogene

Published: August 15, 2024

A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer.

A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 05, 2023

Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors.

Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors.

Journal: The American journal of gastroenterology

Published: February 02, 2023

Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation.

Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation.

Journal: BJU international

Published: February 10, 2021

Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.

Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.

Journal: Cancer medicine

Published: December 03, 2020

A Limited-Versus-Extensive Staging Strategy for Small Cell Prostate Cancer.

A Limited-Versus-Extensive Staging Strategy for Small Cell Prostate Cancer.

Journal: American journal of clinical oncology

Published: November 26, 2019

Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy.

Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy.

Journal: Cancer chemotherapy and pharmacology

Published: May 25, 2017

Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien System.

Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien System.

Journal: Clinical genitourinary cancer

Published: August 19, 2015

Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience.

Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience.

Journal: Oncogene

Published: October 31, 2014

Showing 1-11 of 11

Last Updated: 09/26/2026